Effects of Exercise Frequency on Muscle Size and Strength in Healthy, Untrained Young Adults (FREQ)
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Cameron Mitchell, PhD
- Numero di telefono: 604-827-2072
- Email: cameron.mitchell@ubc.ca
Luoghi di studio
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 1Z1
- Reclutamento
- University of British Columbia | Gateway Health Building
-
Contatto:
- Cameron Mitchell, PhD
- Numero di telefono: 604-827-2072
- Email: cameron.mitchell@ubc.ca
-
Contatto:
- Email: hdennis@student.ubc.ca
-
Sub-investigatore:
- Haley Dennis, MSc
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
- Adulto
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Can fluently read and write in English
- Lives, works, and/or studies at or near the Gateway Health Building (where all study visits will occur)
- Willing and able to commit to 2 or 10 in-person training sessions per week for 10 continuous weeks, as well as one week of testing before the training period and one week of testing after the training period
- Has continuous access to smartphone or other device that they can use to access the Technogym app
- Answers "No" to all questions on the Canadian Society for Exercise Physiology - Get Active Questonnaire (CSEP-GAQ) or has their doctor's approval to participate
Exclusion Criteria:
- Any major uncontrolled cardiovascular, muscular, metabolic, and/or neurological disorders
- Lung disease, kidney disease, or liver disease
- Current diagnosis of type 1 diabetes, type 2 diabetes, or cancer
- Medical conditions that limit their ability to undertake strenuous physical activity
- Regular use of any medications that may affect muscle physiology or body composition (i.e. benzodiazepines, hormone replacement therapy, ADHD medication, Metformin, Ozempic)
- Participated in consistent resistance exercise training more than twice per month in the previous 12 months
- Participated in consistent moderate or vigorous aerobic training more than twice per week in the previous 12 months, or planning to start consistent training in the next few months
- Significant gain or loss of body mass in the past 6 months (greater than 2 kg)
- Current smoker (including but not limited to cigarettes, e-cigarettes, or vaping)
- Body Mass Index of less than 18 kg/m2 or over 30 kg/m2
- Pregnancy or breastfeeding
- Currently taking blood thinners
- Allergic to Tegaderm medical tape (used with the activity trackers)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Standard-frequency resistance training
|
Full-body resistance training consisting of 10 sets per week for all major muscle groups with progressive overload in a gym-based setting.
Training at an exercise frequency of two sessions per week (around 45-60 minutes per session).
|
|
Sperimentale: High-frequency resistance training
|
Full-body resistance training consisting of 10 sets per week for all major muscle groups with progressive overload in a gym-based setting.
Training at an exercise frequency of 10 brief sessions per week (around 8-12 minutes per session).
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Change in Total Body Skeletal Muscle Mass Measured using the D3-Creatine Dilution Method
Lasso di tempo: From enrolment (Week 1) to the end of the exercise training phase (Week 12)
|
From enrolment (Week 1) to the end of the exercise training phase (Week 12)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Total Body Muscle Size Measured as Cross-sectional Area using Muscle Ultrasound Imaging
Lasso di tempo: From enrolment (Week 1) to the end of the exercise training phase (Week 12)
|
Muscle ultrasound imaging will be conducted on one randomly selected side of the body (left or right) for each participant.
Scans will be analyzed to determine the cross-sectional area of the following seven muscles: rectus femoris, vastus lateralis, biceps brachii, pectoralis major, latissimus dorsi, triceps brachii, and hamstring group (semitendinosus, semimembranosus, and long head of biceps femoris).
|
From enrolment (Week 1) to the end of the exercise training phase (Week 12)
|
|
Change in Muscle Strength Measured as the One-Repetition Maximum of Back Squat and Bench Press
Lasso di tempo: From enrolment (Week 1) to the end of the exercise training phase (Week 12)
|
One-repetition maximums will be measured using a Quantum Synchro Smith Machine.
|
From enrolment (Week 1) to the end of the exercise training phase (Week 12)
|
|
Change in Skeletal Muscle Power Measured at Various Relative Loads for Back Squat and Bench Press
Lasso di tempo: From enrolment (Week 1) to the end of the exercise training phase (Week 12)
|
At enrolment (Week 1), power will be measured using a Quantum Synchro Smith Machine at 40%, 50%, 60%, 70%, and 80% of the participant's initial one-repetition maximum (1RM) for back squat and bench press.
At the end of the exercise training phase (Week 12), if a participant's 1RM has increased by less than 25%, power will be measured at the same relative loads.
If a participant's 1RM has increased by 25-49%, power will be measured at 50%, 60%, 70%, 80%, and 90% of the participant's initial 1RM (in this case, 90% of the participant's initial 1RM would not exceed 80% of the participant's post-training 1RM).
If a participant's 1RM has increased by 50% or greater, power will be measured at 60%, 70%, 80%, 90%, and 100% of the participant's initial 1RM (in this case, 100% of the participant's initial 1RM would not exceed 80% of the participant's post-training 1RM).
|
From enrolment (Week 1) to the end of the exercise training phase (Week 12)
|
|
Participant Satisfaction with the Exercise Program
Lasso di tempo: At the end of the exercise training phase (Week 12)
|
Participant satisfaction with the exercise program will be measured using a modified Intrinsic Motivation Inventory (subscales of "Interest/Enjoyment", "Percieved Competence", "Effort/Importance", and "Value/Usefullness").
|
At the end of the exercise training phase (Week 12)
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- H26-01331
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .